Overall, the collective findings from this Phase 1b clinical trial provide the Company with strong confidence that LTI-03 has ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

“A highlight to this quarter’s progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is ...

Panagiotis Tarinidis has unofficially exceeded the U66KG IPF Raw Total World Record with a score of 713 kilograms (1,571.9 ...

The Association of Real Estate Funds (AREF), the British Property Federation (BPF) and the Investment Property Forum (IPF) ...

Hit franchises are transitioning between theatrical releases and OTT platforms, allowing deeper narratives and character ...

About Hydronidone (F351) F351 is a structural analogue of the approved anti-fibrotic (IPF) drug Pirfenidone and has been shown to inhibit in vitro both p38γ kinase activity and TGF-β1-induced ...